Search
Spyre Therapeutics Inc
SYREAdd to Watchlist
103.860USD
+7.270+7.53%
Close 11-06 16:00（ET）
9.57BMarket Cap
LossP/E TTM
Spyre Therapeutics Inc (SYRE) Stock Price Target & Forecast
Analyst Rating
Based on 17 analysts giving stock ratings to Spyre Therapeutics Inc in the past month.
Buy
9 Strong Buy
7 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
123.462USD+27.86%
SYRE Analyst Recommendation Trends
In the current month, SYRE has received 7 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. SYRE average Analyst price target in the last month is 123.462.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
9
9
9
10
10
10
9
9
7
7
7
7
7
7
6
6
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17
17
17
17
17
17
15
15
SYRE Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Biontech SE
BNTX
4
12
6
0
0
22
IQVIA Holdings Inc
IQV
8
13
1
0
0
22
Financial Forecasting
Based on analysts' estimates, SYRE EPS is projected to reach -0.893 in FY2026Q4, following reported EPS of -1.087 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.67
-0.76
-0.83
-0.89
-0.85
Actual
-0.88
-0.43
-1.09
--
--
Surprise
-31.89%
+43.69%
-30.36%
--
--
FAQs
What is Spyre Therapeutics Inc's price target?
Analysts forecast that Spyre Therapeutics Inc's price target is USD 122.79, with the highest forecast at USD 135.00 and the lowest forecast at USD 114.00.
How have Spyre Therapeutics IncSYRE's recent earnings per share performed?
The market expectation was USD -1.09, while Spyre Therapeutics IncSYRE's earnings per share (EPS) for the previous quarter was USD -0.43. EPS for the next quarter is expected at USD -0.89.
What is the analyst rating for Spyre Therapeutics Inc?
Based on the ratings of Spyre Therapeutics Inc's stock from 17 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.